Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1930868 | 0.87 | KDR (0.35) | KDRMEN1KMT2APDGFRBKIT | |
| SCHEMBL4680006 | 0.87 | KDR (0.35) | KDRMEN1KMT2APDGFRBKIT | |
| SCHEMBL1929839 | 0.85 | KDR (0.42) | KDRKDM1AMAOAMAOBMEN1 | |
| SCHEMBL4834682 | 0.72 | CYP11B1 (0.31) | — | |
| SCHEMBL4679265 | 0.71 | KDM4E (0.40) | KDRMEN1KMT2APDGFRBKIT | |
| SCHEMBL1931665 | 0.71 | KDM4E (0.40) | KDRMEN1KMT2APDGFRBKIT | |
| SCHEMBL1930677 | 0.70 | SHMT2 (0.42) | KDRMEN1KMT2ASHMT2PDGFRB | |
| SCHEMBL4740445 | 0.70 | KDR (0.33) | KDRMEN1KMT2APDGFRBKIT | |
| SCHEMBL4740449 | 0.70 | KDR (0.33) | KDRMEN1KMT2APDGFRBKIT | |
| SCHEMBL1931675 | 0.70 | KDR (0.44) | KDRKDM1AMAOAMAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034814-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| US-20110130399-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20090076003-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | NOVARTIS AG | 2009-03-19 | — | — | US | disclosed |
| US-7399761-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | disclosed |
| EP-1387836-B1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076003-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | KDR, FLT1, FLT4 | KDR 1/4885KDM1A 2712/4885MAOA 2064/4885 |
| US-20110130399-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | KDR, FLT1, FLT4 | KDR 1/4885KDM1A 2602/4885MAOA 2549/4885 |
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | VEGFA, NR5A1, PGF | KDR 13/4885KDM1A 2096/4885MAOA 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.